92 related articles for article (PubMed ID: 32725685)
1. Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma.
Takahashi A; Namikawa K; Ogata D; Nakano E; Jinnai S; Nakama K; Tsutsui K; Muto Y; Mizuta H; Yamazaki N
J Dermatol; 2020 Nov; 47(11):1267-1275. PubMed ID: 32725685
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Nivolumab and Ipilimumab Combined Therapy as a First-Line Therapy for Patients with Advanced Melanoma and the Urgent Need for an Effective Second-Line Therapy for Patients with Wild-Type BRAF in Japan: A Single Center Retrospective Study.
Muto I; Koga H; Doi R; Katayama E; Nakama K; Nakama T
Kurume Med J; 2023 Nov; 69(1.2):75-80. PubMed ID: 37793888
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
Najjar YG; Navrazhina K; Ding F; Bhatia R; Tsai K; Abbate K; Durden B; Eroglu Z; Bhatia S; Park S; Chowdhary A; Chandra S; Kennedy J; Puzanov I; Ernstoff M; Vachhani P; Drabick J; Singh A; Xu T; Yang J; Carvajal R; Manson D; Kirkwood JM; Cohen J; Sullivan R; Johnson D; Funchain P; Shoushtari A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581057
[TBL] [Abstract][Full Text] [Related]
4. Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma.
van Not OJ; Verheijden RJ; van den Eertwegh AJM; Haanen JBAG; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; de Groot JB; Hospers GAP; Kamphuis AM; Kapiteijn E; May AM; de Meza MM; Piersma D; van Rijn R; Stevense-den Boer MA; van der Veldt AAM; Vreugdenhil G; Blokx WAM; Wouters MJM; Suijkerbuijk KPM
JAMA Oncol; 2022 Dec; 8(12):1794-1801. PubMed ID: 36301521
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the combined use of ipilimumab and nivolumab for melanoma patients with brain metastases: a systematic review and meta-analysis.
Su M; Yang Y; Wang P
Immunopharmacol Immunotoxicol; 2023 Dec; 45(6):761-769. PubMed ID: 37228242
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced melanoma: a systematic review and meta-analysis.
Cui S; Sun X; Gao J
Expert Rev Anticancer Ther; 2024 May; 24(5):283-291. PubMed ID: 38532600
[TBL] [Abstract][Full Text] [Related]
7. First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
Imai H; Kijima T; Azuma K; Kishi K; Saito H; Yamaguchi T; Tanizaki J; Yoneshima Y; Fujita K; Watanabe S; Kitazono S; Fukuhara T; Hataji O; Toi Y; Mizutani H; Hamakawa Y; Maemondo M; Ohsugi T; Suzuki K; Horinouchi H; Ohe Y
Jpn J Clin Oncol; 2024 Apr; 54(4):452-462. PubMed ID: 38271158
[TBL] [Abstract][Full Text] [Related]
8. Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study.
Kirkwood JM; Kottschade LA; McWilliams RR; Khushalani NI; Jang S; Hallmeyer S; McDermott DF; Tawbi H; Che M; Lee CH; Ritchings C; Le TK; Park B; Ramsey S
Immunotherapy; 2024 Jan; 16(1):29-42. PubMed ID: 37937397
[TBL] [Abstract][Full Text] [Related]
9. Usage of nivolumab and ipilimumab for recurrent or advanced malignant vaginal melanoma: a two-case series.
Konishi K; Okamoto M; Tokumitsu R; Yano M; Nasu K; Kobayashi E
Med Mol Morphol; 2024 Jun; 57(2):83-90. PubMed ID: 38289480
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma.
Dumoulin DW; Douma LH; Hofman MM; van der Noort V; Cornelissen R; de Gooijer CJ; Burgers JA; Aerts JGJV
Lung Cancer; 2024 Jan; 187():107440. PubMed ID: 38104353
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids.
Manacorda S; Carmena MT; Malone C; Linh Le HM; Furness AJS; Larkin J; Schmitt AM
Eur J Cancer; 2023 Jul; 188():98-107. PubMed ID: 37229837
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma.
Thomas B; Burns M; Pervanas H; Ciurescu D; Dima L
Am J Ther; 2023 Nov-Dec 01; 30(6):e526-e534. PubMed ID: 37921680
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan.
Wu CE; Yang CK; Peng MT; Huang PW; Lin YF; Cheng CY; Chang YY; Chen HW; Hsieh JJ; Chang JW
Front Oncol; 2020; 10():905. PubMed ID: 32582554
[No Abstract] [Full Text] [Related]
14. Pediatric model-based dose optimization using a pooled exposure-response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma.
Du S; Zhao Y; Hu Z; Liu S; Roy A; Shen J; Zhu L; Hamuro L
CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):168-179. PubMed ID: 37873561
[TBL] [Abstract][Full Text] [Related]
15. The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
Mallardo D; Woodford R; Menzies AM; Zimmer L; Williamson A; Ramelyte E; Dimitriou F; Wicky A; Wallace R; Mallardo M; Cortellini A; Budillon A; Atkinson V; Sandhu S; Olivier M; Dummer R; Lorigan P; Schadendorf D; Long GV; Simeone E; Ascierto PA
J Transl Med; 2023 Oct; 21(1):753. PubMed ID: 37880788
[TBL] [Abstract][Full Text] [Related]
16. Safety of shortened infusion times for combined ipilimumab and nivolumab.
Gassenmaier M; Lipp HP; Scheu A; Wagner NB; Kofler L; Mueller A; Doecker D; Eigentler TK; Garbe C; Forschner A
Cancer Immunol Immunother; 2018 Jan; 67(1):135-140. PubMed ID: 28988363
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma.
Conduit C; Davis ID; Goh JC; Kichenadasse G; Gurney H; Harris CA; Pook D; Krieger L; Parnis F; Underhill C; Adams D; Roncolato F; Joshua A; Ferguson T; Prithviraj P; Morris M; Harrison M; Begbie S; Hovey E; George M; Liow EC; Link EK; McJannett M; Gedye C; ;
BJU Int; 2024 Feb; 133 Suppl 3():57-67. PubMed ID: 37986556
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis.
Heppt MV; Eigentler TK; Kähler KC; Herbst RA; Göppner D; Gambichler T; Ulrich J; Dippel E; Loquai C; Schell B; Schilling B; Schäd SG; Schultz ES; Matheis F; Tietze JK; Berking C
Cancer Immunol Immunother; 2016 Aug; 65(8):951-9. PubMed ID: 27294607
[TBL] [Abstract][Full Text] [Related]
19. SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma.
Kottschade LA; Pond GR; Olszanski AJ; Zakharia Y; Domingo-Musibay E; Hauke RJ; Curti BD; Schober S; Milhem MM; Block MS; Hieken T; McWilliams RR
Clin Cancer Res; 2023 Jun; 29(12):2220-2225. PubMed ID: 37000165
[TBL] [Abstract][Full Text] [Related]
20. Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma.
Lutzky J; Sullivan RJ; Cohen JV; Ren Y; Li A; Haq R
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6059-6066. PubMed ID: 36651961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
